Device
Ologen
Ologen is a medical device with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(67%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
2
67%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (66.7%)
N/A1 (33.3%)
Trials by Status
completed133%
terminated267%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_2
The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)
NCT02990143
completedphase_2
Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C
NCT03506542
terminatednot_applicable
Trabeculectomy With Ologen
NCT01753492
Clinical Trials (3)
Showing 3 of 3 trials
NCT02990143Phase 2
The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)
NCT03506542Phase 2
Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C
NCT01753492Not Applicable
Trabeculectomy With Ologen
All 3 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 3